Navigating Radiopharmaceutical Reimbursement in Canada скачать в хорошем качестве

Navigating Radiopharmaceutical Reimbursement in Canada

Canada has long been a global isotope leader, with historic milestones that include the world’s first-ever cancer treatment using cobalt-60 and unique advantages such as the CANDU nuclear power reactor. Despite this long history of isotope innovation across the country, ensuring that all Canadians have publicly funded access to new radiopharmaceuticals for the treatment of diseases such as cancer has proven to be a time-consuming process. While some progress has been made, with radiopharmaceuticals such as Pluvicto and Lutathera now being funded by public health plans in several provinces across Canada, more work is needed to ensure that all Canadians can access these life-changing drugs as soon as they are approved by Health Canada. Join us on September 25th for a timely panel discussion featuring Canadian radiopharmaceutical and isotope industry leaders. These leaders will discuss the progress we have seen so far, the opportunities for further expansion of radiopharmaceuticals in publicly funded healthcare across the country, and the important role that nuclear medicine will play in cancer care for years to come.